Ajit Dave, MD
Hematology & Oncology · Denton, TXNPI 1043291347
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), education and speaking fees — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Daiichi Sankyo Inc. at 54.4% of the total. 2025 is the largest year on record at $750, more than ten times the $60 reported in 2020. That places this record below the midpoint for hematology & oncology clinicians in TX, where the typical reported total is $3,204.
Across 20 payments — averaging $107.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$1K
- Sanofi$350
- Johnson & Johnson$254
- Sobi, Inc$114
- Astellas Pharma US Inc$104
- Lilly USA, LLC$77
- plus $85 from 4 others
What the payments were for
- Consulting fees$1,17554%
- Speaking & faculty fees$35016%
- Food & beverage$21010%
- Education$42420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 2 | $1,175 |
| Sanofi | 1 | $350 |
| Johnson & Johnson | 4 | $254 |
| Sobi, Inc | 2 | $114 |
| Astellas Pharma US Inc | 2 | $104 |
| Lilly USA, LLC | 4 | $77 |
| Novartis | 2 | $31 |
| Boehringer Ingelheim | 1 | $28 |
| Puma Biotechnology, Inc. | 1 | $13 |
| Acrotech Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,159 in reported general payments places this provider in the 40th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 11 | $14,045 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,470 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,032 |
| Celecoxib | 13 | $886 |
| Pregabalin | 11 | $405 |
| Omeprazole | 13 | $393 |
| Metformin Hcl | 57 | $343 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $341 |
| Levothyroxine Sodium | 35 | $329 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $290 |
| Atorvastatin Calcium | 39 | $249 |
| Pantoprazole Sodium | 19 | $231 |
| CefuroximeCefuroxime Axetil | 13 | $213 |
| Methylprednisolone | 27 | $211 |
| Tamsulosin Hcl | 26 | $201 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Denton
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Asad DeanFort Worth$1.1M
- Habte YimerTyler$934K
- Edward PearsonDallas$900K
- Naval DaverHouston$853K
- Christopher MaiselDallas$713K
- Clifton LaymanEl Paso$645K
- Jorge Cortes-FrancoHouston$627K
- Timothy FenskeSan Antonio$626K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.